Suppr超能文献

经皮给药技术介导药物治疗骨关节炎的研究进展与挑战

Progress and Challenges of Topical Delivery Technologies Meditated Drug Therapy for Osteoarthritis.

机构信息

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China.

Jinhua Institute of Zhejiang University, Jinhua, Zhejiang, 321299, People's Republic of China.

出版信息

Int J Nanomedicine. 2024 Aug 14;19:8337-8352. doi: 10.2147/IJN.S466437. eCollection 2024.

Abstract

Osteoarthritis (OA) is a degenerative disease commonly seen in middle-aged and elderly people. Multiple cytokines are involved in the local tissue damage in OA. Currently, non-pharmacologic and surgical interventions are the main conventional approaches for the treatment of OA. In terms of pharmaceutical drug therapy, NSAIDs and acetaminophen are mainly used to treat OA. However, it is prone to various adverse reactions such as digestive tract ulcer, thromboembolism, prosthesis loosening, nerve injury and so on. With the in-depth study of OA, more and more novel topical drug delivery strategies and vehicles have been developed, which can make up for the shortcomings of traditional dosage forms, improve the bioavailability of drugs, and significantly reduce drug side effects. This review summarizes the immunopathogenesis, treatment guidelines, and progress and challenges of topical delivery technologies of OA, with some perspectives on the future pharmacological treatment of OA proposed.

摘要

骨关节炎(OA)是一种常见于中老年人的退行性疾病。多种细胞因子参与 OA 的局部组织损伤。目前,非药物和手术干预是 OA 治疗的主要常规方法。在药物治疗方面,非甾体抗炎药和对乙酰氨基酚主要用于治疗 OA。然而,它容易发生各种不良反应,如消化道溃疡、血栓栓塞、假体松动、神经损伤等。随着对 OA 的深入研究,越来越多的新型局部药物递送策略和载体被开发出来,可以弥补传统剂型的不足,提高药物的生物利用度,显著降低药物的副作用。本文综述了 OA 的免疫发病机制、治疗指南以及局部递药技术的进展和挑战,并对 OA 的未来药物治疗提出了一些看法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5edf/11330747/81c00019792e/IJN-19-8337-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验